Key Takeaways ABBV's Skyrizi and Rinvoq are driving growth, offsetting losses from Humira's patent expiration. ABBV gained new drug approvals and expanded its oncology and neuroscience portfolios via acquisitions. BMY faces revenue pressure from legacy drugs despite new launches like Cobenfy and Opdualag growth.AbbVie, Inc. (ABBV) and Bristol Myers Squibb (BMY) are leading drugmakers with broad and diverse portfolios and a global footprint.AbbVie is a global, diversified biopharmaceutical company with a d ...